(Q33287330)

25 July 2017

title

Parity, pregnancy and neonatal outcomes in women treated for hyperprolactinaemia compared with a control group (English)

1 reference

Angelica Lindén Hirschberg

25 July 2017

1 reference

2

Anna-Lena Hulting

0 references

series ordinal

4

object named as

Angelica Lindén Hirschberg

1 reference

25 July 2017

Katarina Berinder

1

0 references

Fredrik Granath

series ordinal

3

object named as

Fredrik Granath

1 reference

25 July 2017

Anna-Lena Hulting

2

1 reference

25 July 2017

Olof Akre

series ordinal

5

1 reference

25 July 2017

publication date

11 June 2007

1 reference

25 July 2017

published in

Clinical Endocrinology

1 reference

25 July 2017

volume

67

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

393-397

1 reference

Dopamine agonists and pituitary tumor shrinkage

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Pituitary tumors and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Outcome and long-term effects of pregnancy in women with hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Long-term follow-up of patients with hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Outcome of pregnancy in mothers given bromocriptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Medical management of prolactin-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Advances in the treatment of prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Pregnancy outcome after treatment with the ergot derivative, cabergoline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Pregnancy outcome after cabergoline treatment in early weeks of gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Quinagolide--a valuable treatment option for hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Medical treatment of prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

Successful treatment of a large macroprolactinoma with cabergoline during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02897.X

10.1111/J.1365-2265.2007.02897.X

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference